Schonfeld Strategic Advisors LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 269 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.

Quarter-by-quarter ownership
Schonfeld Strategic Advisors LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$250,324
-76.6%
6,553
-76.6%
0.00%
-80.0%
Q1 2023$1,069,052
-94.3%
27,993
-91.5%
0.01%
-93.6%
Q4 2022$18,822,520
+22.3%
330,800
-15.0%
0.16%
+21.7%
Q3 2022$15,390,000
+19.1%
389,231
+32.6%
0.13%
+3.2%
Q2 2022$12,920,000
+60.5%
293,638
+45.5%
0.12%
+73.6%
Q1 2022$8,048,000
+7.8%
201,805
+8.6%
0.07%
+5.9%
Q4 2021$7,469,000
+31.2%
185,768
+32.7%
0.07%
+15.3%
Q3 2021$5,695,000
-48.9%
140,000
-43.0%
0.06%
-50.4%
Q2 2021$11,152,000
+54.3%
245,600
+41.6%
0.12%
+35.2%
Q1 2021$7,229,000
+305.7%
173,401
+315.5%
0.09%
+266.7%
Q4 2020$1,782,000
-5.7%
41,738
-41.9%
0.02%
-33.3%
Q3 2020$1,890,000
-41.6%
71,900
-40.5%
0.04%
-16.3%
Q2 2020$3,238,000
+550.2%
120,782
+336.0%
0.04%
+38.7%
Q1 2020$498,000
-49.3%
27,705
-51.6%
0.03%
-11.4%
Q2 2019$983,000
-65.4%
57,200
-67.6%
0.04%
-64.6%
Q1 2019$2,844,000
+746.4%
176,576
+667.7%
0.10%
+661.5%
Q4 2018$336,000
-51.7%
23,000
-67.3%
0.01%
-85.6%
Q4 2016$696,00070,4280.09%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,305,403$233,209,00010.86%
BB BIOTECH AG 7,379,832$89,148,0003.13%
SENZAR ASSET MANAGEMENT, LLC 550,544$6,650,572,0001.72%
SNYDER CAPITAL MANAGEMENT L P 2,232,114$26,964,0001.69%
Sterling Global Strategies LLC 22,000$266,0000.98%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,290,024$112,223,0000.98%
MSD Partners, L.P. 965,000$11,657,0000.94%
DOHENY ASSET MANAGEMENT /CA 130,950$1,582,0000.81%
Taylor Wealth Management Partners 128,110$1,548,0000.69%
Bellevue Group AG 318,000$3,841,0000.69%
View complete list of HALOZYME THERAPEUTICS INC shareholders